Nature Medicine
June 1, 2021
Jennifer Mitchell, Michael P. Bogenschutz, Alia Lilienstein et al.
965 citations
Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with...
Cureus
May 17, 2021
Sarah Tedesco, Ganeya Gajaram, Shahzad Chida et al.
31 citations
Background: 3,4-methylenedioxymethamphetamine (MDMA), known recreationally as "Molly" or "Ecstasy", is a triple monoamine reuptake inhibitor. MDMA specifically acts as a weak 5-HT1 and 5-HT2 receptor agonist, targeting 5-HT2A, 5-HT2B, and 5-HT2C receptors. Its potential use for therapeutic purposes with these pharmacological profiles remains a controversial subject. Studies have shown the...
European Psychiatry
April 1, 2021
B. Van der Kolk
Introduction Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Previous research has led to the designation of 3,4-methylenedioxymethamphetamine (MDMA) as a Breakthrough Therapy for treatment of post-traumatic stress disorder (PTSD) when administered as an adjunct to psychotherapy....
European Psychiatry
April 1, 2021
I. Figueiredo, Filipa Viegas, F. Ferreira et al.
2 citations
Introduction Post-traumatic stress disorder (PTSD) is often a chronic condition, despite the existence of evidence-based treatment options. Psychotherapy is the designated first line treatment for PTSD, although high rates of psychiatric and medical comorbidity are observed among patients who have undergone treatment. The psychoactive properties of psychedelics may be of particular interest...
Mental Health Weekly
February 15, 2021
Valerie A. Canady
Prior use of selective serotonin reuptake inhibitors (SSRIs) may reduce the effectiveness of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted therapy for post‐traumatic stress disorder (PTSD), say researchers of a recent study who noted that MDMA is close to being considered the first psychedelic drug approved to treat PTSD.
Acta Iuris Stetinensis
2021
Konrad Burdziak
Przedmiotem pracy uczyniono problematykę leczenia PTSD z wykorzystaniem MDMA jako sposobu przeciwdziałania zjawisku samobójstwa. Rozważania w tym zakresie przeprowadzono na tle polskiego prawa. W pracy wykorzystano metodę dogmatycznoprawną. Zdecydowano się przy tym skorzystać z derywacyjnej koncepcji wykładni prawa autorstwa M. Zielińskiego. Autor pracy ustalił, że: 1) PTSD może stanowić źródło...
European Journal of Psychotraumatology
2021
Lukas A Basedow, Sören Kuitunen-Paul, Melina Wiedmann et al.
15 citations
ABSTRACT Background: Adolescent patients with a substance use disorder (SUD) often fulfil the criteria for a co-occurring post-traumatic stress disorder (PTSD). However, it is not clear if these dual-diagnosed adolescents present with unique levels of substance use and how their substance use relates to PTSD symptom clusters. Objective: To investigate substance use in adolescents with...
Psychology and Behavioral Sciences
2021
Brenda Tichler
The importance of treating concurrent Post-Traumatic Stress Disorder (PTSD) and substance use with psychedelics is a controversial topic, hampered in part by a lack of empirical evidence and rigidity of substance scheduling. Traditional treatments for concurrent PTSD and substance use concerns are compartmentalized, with clinicians focusing on one condition over the other. In addition,...
Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)
2021
Alvaro V Jardim, Dora V Jardim, Bruno Rasmussen Chaves et al.
54 citations
To conduct Brazil's first clinical trial employing 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder (PTSD), given its high prevalence resulting from epidemic violence. Of 60 volunteers, four matched the inclusion & exclusion criteria. Three patients with PTSD secondary to sexual abuse (diagnosed by the Structured Clinical Interview for DSM-IV...
Medical Hypotheses
2021
Timothy D Brewerton, Adele Lafrance, Michael C Mithoefer
28 citations
Despite advances in the field, eating disorders (EDs) remain very challenging disorders to treat, especially when comorbid with posttraumatic stress disorder (PTSD). N-methyl-3,4-methylenedioxyamphetamine (MDMA)-assisted psychotherapy for treatment refractory PTSD shows great promise, with two-thirds of participants achieving full remission at 1 year or more at follow-up. PTSD is a common...